Four-year epidemiological study of extended-spectrum β-lactamase-producing Enterobacteriaceae in a French teaching hospital.
Since the end of the last century resistance to oxyimino β-lactams has steadily increased in Enterobacteriaceae. In the present work we studied extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae strains isolated in the teaching hospital of Clermont-Ferrand, France, between 2006 and 2009. A total of 1368 ESBL-producing isolates were collected. Most of these isolates (69%) were CTX-M-producing Escherichia coli. During the study, the clinical incidence increased by more than 400%, even in the emergency department, and especially in community-acquired infections, as is the case elsewhere in the world. Most of the ESBL-producing isolates remained susceptible to furans and fosfomycin, but only 50% to fluoroquinolons. In conclusion, ESBL-producing bacteria constantly increased during the study period. Unlike many studies, this increase was associated with the wide dissemination of three different CTX-M enzymes: CTX-M-14, CTX-M-15 and CTX-M-1.
Laboratoire de Bactériologie, CHU Clermont-Ferrand, Centre de Biologie, Clermont-Ferrand, France; Microbes, Intestins, Inflammation et Susceptibilité de l'Hôte, INSERM U1071, INRA, USC2018, Clermont Université, Université d'Auvergne, Clermont-Ferrand, France.
L
L
Gibold
F
F
Robin
R-N
RN
Tan
J
J
Delmas
R
R
Bonnet
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017714:Community-Acquired Infections / Q000453:epidemiology / Q000382:microbiology; D024881:Drug Resistance, Bacterial; D024901:Drug Resistance, Multiple, Bacterial; D004755:Enterobacteriaceae / Q000145:classification / Q000201:enzymology* / Q000302:isolation & purification; D004756:Enterobacteriaceae Infections / Q000453:epidemiology / Q000382:microbiology*; D004926:Escherichia coli / Q000145:classification / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000453:epidemiology / Q000401:mortality; D024841:Fluoroquinolones / Q000494:pharmacology; D005578:Fosfomycin / Q000494:pharmacology; D005602:France / Q000453:epidemiology; D005663:Furans / Q000494:pharmacology; D006784:Hospitals, Teaching; D006801:Humans; D008826:Microbial Sensitivity Tests; D012189:Retrospective Studies; D001618:beta-Lactamases / Q000235:genetics / Q000378:metabolism*
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D005663:Furans; D005578:Fosfomycin; C456080:beta-lactamase CTX-M-14; C473109:beta-lactamase CTX-M-15; C055184:beta-lactamase TEM-3; D001618:beta-Lactamases
Antibiotic resistance; Enterobacteriaceae; Escherichia coli; extended-spectrum β-lactamase; β-lactamase